The Latest Cardiac and Vascular News
NEW YORK, Nov. 19, 2024 /PRNewswire/ — Remedy Pharmaceuticals, a leader in stroke drug development, announced today that a Type C meeting held with the U.S. Food and Drug Administration (FDA) on October 16, 2024, provided valuable feedback on the design of a Phase 3 trial of its…
VAPI, India, Nov. 19, 2024 /PRNewswire/ — Meril, a global leader in cutting-edge cardiovascular and structural heart solutions, is renowned for its next-generation transcatheter heart valve technologies. Upholding its commitment to innovation, Meril continues to drive advancements in…
ROME, Nov. 19, 2024 /PRNewswire/ — A comprehensive study led by Professor Dr. Achille Gaspardone was presented at the 2024 TCT Congress which, demonstrated the exceptional efficacy of the Noblestitch™ suture-mediated Patent Foramen Ovale (PFO) closure system in preventing recurrent…
Muvalaplin, an oral, once-daily treatment that inhibits lipoprotein(a) formation via a novel mechanism, achieved positive results in a 12-week Phase 2 study These data were published in the Journal of the American Medical Association (JAMA) and simultaneously presented today at the…
– Acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the ATTRibute-CM study (3 months), with statistically significant risk reduction of 36% on All-Cause Mortality (ACM) alone at Month 36 within the Open Label Extension
– sdATEVs maintained sustained patency throughout the six-month study –
SOUTH SAN FRANCISCO, Calif., Nov. 16, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data from post-hoc analyses of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), the Phase 3 cardiovascular outcomes clinical trial of omecamtiv mecarbil were presented at the American Heart Association Scientific Sessions 2024 in Chicago, IL.
Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor class Study results add to the growing body of evidence differentiating sotagliflozin within SGLT inhibitor class
BETHESDA, Md., Nov. 12, 2024 (GLOBE NEWSWIRE) — CorVista Health, Inc., a leading digital health company dedicated to improving cardiovascular disease diagnosis, today announced the signing of a Memorandum of Understanding (MOU) with Advanced Telecommunications Solutions and Services (ATSS) to explore the potential of introducing the CorVista® System into the Kingdom of Saudi Arabia. The CorVista System is the world’s first point-of-care system for evaluating the presence of significant coronary artery disease (CAD) and pulmonary hypertension (PH) in a single visit.
Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data…
